Dimitrov D
Vutr Boles. 1985;24(3):72-6.
Thirty two patients with essential hypertension, stage I and II according to WHO classification, were treated according to the following schedule: period A--3 X 1 dragée placebo--3 weeks; period B--3 X 1 dragée placebo + 25 mg hydrochlorothiazide in the morning--6 weeks; period C--3 X 1 dragée isoptin 80 mg + 25 mg hydrochlorothiazide in the morning--6 weeks; period D--3 X 1 dragée placebo--2 weeks. Significant decrease of systolic and diastolic arterial pressure was established during period B as compared with period. A. The addition of isoptin to the treatment during period C led to additional reduction of arterial pressure, with no manifestations of severe adverse effects, as observed in 15,6 per cent of the treated patients. The treatment of essential hypertension with isoptin and esidrex is effective and well tolerated with no reciprocal potentiation of the adverse effects of the two preparations, broadening the possibility of successful treatment of essential hypertension.
32例根据世界卫生组织分类为I期和II期的原发性高血压患者，按照以下方案进行治疗：A期——每日3次，每次1片安慰剂，共3周；B期——每日3次，每次1片安慰剂加早上服用25毫克氢氯噻嗪，共6周；C期——每日3次，每次1片80毫克异搏定加早上服用25毫克氢氯噻嗪，共6周；D期——每日3次，每次1片安慰剂，共2周。与A期相比，B期收缩压和舒张压显著降低。C期治疗中加入异搏定导致血压进一步降低，未观察到严重不良反应，15.6%的治疗患者出现该情况。用异搏定和氢氯噻嗪治疗原发性高血压有效且耐受性良好，两种制剂的不良反应无相互增强作用，拓宽了成功治疗原发性高血压的可能性。
